A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection

Journal of Immunological Methods

Volumn 314, Issue 1-2, 2006, Pages 74-79

  Lu, Yanmei ^a   Wong, Wai Lee ^a   Meng, Y Gloria ^a  

^a GENENTECH INC   (United States)

Author keywords

Anti CD20; Carbon surface plate; Cell binding assay; Electrochemiluminescence; Humanized antibody; WIL2 cells

Indexed keywords

CD20 ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CELL ASSAY; CELL BINDING ASSAY; CELL CLONE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUSPENSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD20; CHO CELLS; CLONE CELLS; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE DOSAGE; LUMINESCENCE; MICE; RECOMBINANT FUSION PROTEINS;

EID: 33746889823     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2006.05.011     Document Type: Article

References (14)

1. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., and Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63 (1984) 1424
2. Baron D., Wernet P., Schunter F., and Wigzell H. Detection and quantitation of human Ia-type antigens with iodinated protein A and specific purification of antibodies against Ia-type alloantigens. Scand. J. Immunol. 6 (1977) 385
3. 2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]. J. Pharmacol. Exp. Ther. 313 (2005) 902
4. Boye J., Elter T., and Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14 (2003) 520
5. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., and Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4285
6. Hong K., Presta L.G., Lu Y., Penn A., Adams C., Chuntharapai A., Yang J., Wong W.L., and Meng Y.G. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Methods 294 (2004) 189
7. Kneitz C., Wilhelm M., and Tony H.P. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 206 (2002) 519
8. Liang P., Sanchez R.I., and Martin M.T. Electrochemiluminescence-based detection of β-lactam antibiotics and β-lactamases. Anal. Chem. 68 (1996) 2426
9. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., and Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593
10. Schlosser M., Witt S., Ziegler B., and Ziegler M. Influence of target cell preparation on binding of monoclonal islet cell reactive antibodies (mc-ICRA) in cellular enzyme-linked immunosorbent assay (CELISA). J. Immunol. Methods 140 (1991) 101
11. Sedgwick J.D., and Czerkinsky C. Detection of cell-surface molecules, secreted products of single cells and cellular proliferation by enzyme immunoassay. J. Immunol. Methods 150 (1992) 159
12. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High-resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276 (2001) 6591
13. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22 (2003) 7359
14. Tedder T.F., Streuli M., Schlossman S.F., and Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 208